The history of the "natural history" of hepatitis C (1968-2009).
about
Pharmacological treatments for chronic hepatitis C liver disease: a network meta-analysisPharmacological treatments for acute hepatitis C infection: a network meta-analysisAminoadamantanes versus other antiviral drugs for chronic hepatitis CAminoadamantanes for chronic hepatitis CAminoadamantanes versus other antiviral drugs for chronic hepatitis CPeginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis CPeginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis CAminoadamantanes for chronic hepatitis CProtease inhibitors in combination with pegylated interferon and ribavirin for adult patients with chronic hepatitis C virusPegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis CA Meta-Analysis of the Association Between the I148M Variant of Patatin-Like Phospholipase Domain Containing 3 Gene and the Presence of Chronic Hepatitis CRegulation of hepatic innate immunity by hepatitis C virusIs sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?Hepatitis C - Assessment to Treatment Trial (HepCATT) in primary care: study protocol for a cluster randomised controlled trial.Influence of host resistance on viral adaptation: hepatitis C virus as a case studyHCV RNA Activates APCs via TLR7/TLR8 While Virus Selectively Stimulates Macrophages Without Inducing Antiviral ResponsesOptimal control of hepatitis C antiviral treatment programme delivery for prevention amongst a population of injecting drug usersRelation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver diseaseHepatitis C virus phylogenetic clustering is associated with the social-injecting network in a cohort of people who inject drugsEligibility of persons who inject drugs for treatment of hepatitis C virus infection.Risk of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey data.Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration.Screening the anti infectivity potentials of native N- and C-lobes derived from the camel lactoferrin against hepatitis C virus.Immune control and failure in HCV infection--tipping the balance.Mortality of patients infected with HIV in the intensive care unit (2005 through 2010): significant role of chronic hepatitis C and severe sepsis.Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate modelInterferon lambda: opportunities, risks, and uncertainties in the fight against HCV.Liver stiffness measurement among patients with chronic hepatitis B and C: results from a 5-year prospective study.The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development.Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991-2010): an age-period-cohort analysisEfficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled TrialsThe relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected womenA prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C.Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection.Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7).Activation and evasion of antiviral innate immunity by hepatitis C virus.Spatiotemporal Scan and Age-Period-Cohort Analysis of Hepatitis C Virus in Henan, China: 2005-2012Assessment of disease progression in patients with transfusion-associated chronic hepatitis C using transient elastography.Hepatitis C Virus Stimulates Murine CD8α-Like Dendritic Cells to Produce Type I Interferon in a TRIF-Dependent MannerPerihepatic lymphadenopathy in children with chronic viral hepatitis
P2860
Q24186846-4AD3A9A8-F633-4419-89CF-FD203FAEDF92Q24186859-525F0175-323B-4A29-BEF7-AA33CD70AE15Q24193940-B1BC6972-14C7-488A-857B-4E4BF48DC6E9Q24194770-2E50267D-810A-494F-A4FC-7BA54040F88CQ24194815-7DED3F21-C8F6-43FE-A1AF-0E59BB296385Q24200189-F072A36F-FD56-48AE-92D8-20DEDA35688FQ24200197-7EE3F165-7DD9-4312-8286-8C7830312415Q24201226-9A19C58A-192A-4EA6-AC10-2B1C0AC4108EQ24202464-19607638-2FCD-42FD-80CD-96FC51AE9687Q24241360-028C1BA1-35EF-4778-9086-6A386FBA4F6DQ26770432-BFE0231E-80B2-4DC6-95F2-342285157BF3Q26824743-B06B281D-D8F6-4BF0-B546-DC0993C71B57Q26830804-37D278D0-88D7-4DC1-8D86-0FF5101ED9E3Q27332215-C6481944-DF3F-4787-8669-5A7DF18EFBAFQ28087595-E8504C89-ECED-48F0-9206-117256766700Q28276935-DFE4220F-07DC-4573-8554-89A722DB9457Q28476518-B074AD66-55C9-4B83-A2DE-EE8028C299A8Q28483964-48B79DD8-3B29-4647-8A9A-7FDD7C43D13AQ28484576-3AF9BA1B-D7CB-4A49-B69D-D71B2132A867Q30429470-B15AA9B5-D776-4A0E-911A-6DACE7B47888Q30713067-010B2906-A440-43D6-95AE-B16CA53B1AE5Q31143582-C74D57F2-4C74-42BA-A9F9-9586634E81FEQ33863096-9107259F-F070-4D5C-AD36-5E855FB27F66Q34178628-A16EEA9A-3FB7-4817-9EC9-45AD638D15DEQ34250648-888DF648-17EB-4132-91FB-AD1E51D49486Q34284247-5BEFF97A-AEB3-4299-94B3-E3357D6B3AB8Q34433087-8AB59DD7-1A05-4FE2-90AB-BD40EE59A1B7Q34450720-FFCE9F7F-5533-470B-9F0B-16A6A85D039AQ34481429-191DC96A-686D-438C-A42C-901B1F547EC5Q34609276-891FFB7D-CD84-4E10-B370-34B5D9F66A62Q34714220-B446D341-E679-4C1F-8CDB-EEAB1EAE7580Q35000910-2CE0B590-E56A-450C-BDE7-9DE4D07084F0Q35131882-328DA08B-AC05-4E21-8373-86C3C243C079Q35205389-02F8C180-FBA0-404D-AD2F-B222A3317AE0Q35547001-0A5A98F8-4A65-4D80-9513-62B8BD894281Q35606341-65260290-C485-4C2A-B8D0-4895D0111100Q35663720-00E349B4-53A6-4B4D-BF57-7F6B8E29FFD8Q35872121-278DCE36-D992-4936-9F7C-FF2DFEC747AAQ36069295-F738C3B8-6EB3-4C3D-9ECE-A8D3655CE502Q36085226-678690D2-A045-43E1-A00B-99902F5F3B9F
P2860
The history of the "natural history" of hepatitis C (1968-2009).
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
The history of the "natural history" of hepatitis C (1968-2009).
@ast
The history of the "natural history" of hepatitis C (1968-2009).
@en
type
label
The history of the "natural history" of hepatitis C (1968-2009).
@ast
The history of the "natural history" of hepatitis C (1968-2009).
@en
prefLabel
The history of the "natural history" of hepatitis C (1968-2009).
@ast
The history of the "natural history" of hepatitis C (1968-2009).
@en
P2860
P1433
P1476
The history of the "natural history" of hepatitis C (1968-2009).
@en
P2093
Leonard B Seeff
P2860
P356
10.1111/J.1478-3231.2008.01927.X
P478
29 Suppl 1
P577
2009-01-01T00:00:00Z